Pharvaris (PHVS) News Today $17.25 +0.56 (+3.36%) Closing price 05/20/2025 04:00 PM EasternExtended Trading$17.35 +0.10 (+0.57%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHVS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Soleus Capital Management L.P. Grows Holdings in Pharvaris (NASDAQ:PHVS)Soleus Capital Management L.P. increased its holdings in Pharvaris (NASDAQ:PHVS - Free Report) by 36.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 814,652 shares of the company's stock aMay 21 at 8:13 AM | marketbeat.comBank of America Securities Keeps Their Sell Rating on Pharvaris (PHVS)May 21 at 6:11 AM | theglobeandmail.comPharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming CongressesMay 19 at 6:50 AM | globenewswire.comPharvaris (NASDAQ:PHVS) Shares Sold by Sphera Funds Management LTD.Sphera Funds Management LTD. trimmed its holdings in Pharvaris (NASDAQ:PHVS - Free Report) by 11.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 388,183 shares of the company's stock after selling 51,May 18 at 7:15 AM | marketbeat.comWedbush Issues Optimistic Forecast for Pharvaris EarningsMay 18 at 1:35 AM | americanbankingnews.comPharvaris (NASDAQ:PHVS) Price Target Cut to $25.00 by Analysts at Cantor FitzgeraldMay 17, 2025 | americanbankingnews.comWhat is Leerink Partnrs' Estimate for Pharvaris Q2 Earnings?May 17, 2025 | americanbankingnews.comPatient Square Capital LP Sells 34,738 Shares of Pharvaris (NASDAQ:PHVS)Patient Square Capital LP cut its holdings in Pharvaris (NASDAQ:PHVS - Free Report) by 14.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 207,603 shares of the company's stock after selling 34,738 shares during the quaMay 16, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Down 5.1% Following Weak EarningsMay 16, 2025 | americanbankingnews.comPharvaris (NASDAQ:PHVS) Shares Acquired by Octagon Capital Advisors LPOctagon Capital Advisors LP raised its holdings in Pharvaris (NASDAQ:PHVS - Free Report) by 25.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 778,000 shares of the companyMay 15, 2025 | marketbeat.comPharvaris (PHVS) Target Price Revised by Cantor Fitzgerald | PHVS Stock NewsMay 14, 2025 | gurufocus.comPharvaris (PHVS) Target Price Lowered by Cantor Fitzgerald | PHVS Stock NewsMay 14, 2025 | gurufocus.comPharvaris (PHVS) Target Price Increased by Wedbush Amid Clinical Progress | PHVS Stock NewsMay 14, 2025 | gurufocus.comPharvaris Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comPharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4May 12, 2025 | globenewswire.comPharvaris (PHVS) Projected to Post Earnings on WednesdayPharvaris (NASDAQ:PHVS) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-pharvaris-nv-stock/)May 9, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Increases Stock Holdings in Pharvaris (NASDAQ:PHVS)Price T Rowe Associates Inc. MD boosted its stake in Pharvaris (NASDAQ:PHVS - Free Report) by 36.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 443,896 shares of the company's stock after acquiring an adMay 6, 2025 | marketbeat.comCantor Fitzgerald Forecasts Pharvaris FY2025 EarningsPharvaris (NASDAQ:PHVS - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Pharvaris in a research report issued on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the company will earn ($3.31) perMay 3, 2025 | marketbeat.comPharvaris (PHVS) Shares Cross Above 200 DMAMay 2, 2025 | nasdaq.comPharvaris (NASDAQ:PHVS) Shares Gap Up - Here's WhyPharvaris (NASDAQ:PHVS) Shares Gap Up - Still a Buy?May 1, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Coverage Initiated by Analysts at Cantor FitzgeraldCantor Fitzgerald began coverage on shares of Pharvaris in a research note on Tuesday. They set an "overweight" rating and a $28.00 price target on the stock.May 1, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Pharvaris N.V. (PHVS) with Overweight RecommendationApril 30, 2025 | msn.comPharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Here's WhyPharvaris (NASDAQ:PHVS) Sees Strong Trading Volume - Still a Buy?April 27, 2025 | marketbeat.comRock Springs Capital Management LP Purchases 18,200 Shares of Pharvaris (NASDAQ:PHVS)Rock Springs Capital Management LP raised its position in shares of Pharvaris (NASDAQ:PHVS - Free Report) by 2.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 775,131 shares of the company's stock afApril 23, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Stock Price Up 7.8% - Still a Buy?Pharvaris (NASDAQ:PHVS) Trading Up 7.8% - Time to Buy?April 17, 2025 | marketbeat.comFmr LLC Has $103.43 Million Holdings in Pharvaris (NASDAQ:PHVS)Fmr LLC increased its position in Pharvaris (NASDAQ:PHVS - Free Report) by 3.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 5,395,370 shares of the company's stock after purchasing an additional 189,714 shares during the period. Fmr LLC owned about 10April 16, 2025 | marketbeat.comQ1 Earnings Estimate for Pharvaris Issued By Leerink PartnrsPharvaris (NASDAQ:PHVS - Free Report) - Analysts at Leerink Partnrs dropped their Q1 2025 EPS estimates for Pharvaris in a report released on Monday, April 7th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($0.91) per share for the quarter, down from thApril 12, 2025 | marketbeat.comWedbush Comments on Pharvaris' Q1 Earnings (NASDAQ:PHVS)Pharvaris (NASDAQ:PHVS - Free Report) - Analysts at Wedbush lowered their Q1 2025 EPS estimates for shares of Pharvaris in a research report issued to clients and investors on Monday, April 7th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($0.92) per share for thApril 12, 2025 | marketbeat.comWhat is Wedbush's Estimate for Pharvaris FY2029 Earnings?Pharvaris (NASDAQ:PHVS - Free Report) - Equities researchers at Wedbush issued their FY2029 EPS estimates for Pharvaris in a research note issued on Monday, April 7th. Wedbush analyst L. Chico forecasts that the company will post earnings of $5.99 per share for the year. The consensus estimate foApril 11, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Hits New 12-Month Low - Here's What HappenedPharvaris (NASDAQ:PHVS) Sets New 12-Month Low - Should You Sell?April 11, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Stock Price Down 8.4% - Here's What HappenedPharvaris (NASDAQ:PHVS) Stock Price Down 8.4% - Here's What HappenedApril 9, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Announces Quarterly Earnings Results, Beats Expectations By $0.06 EPSPharvaris (NASDAQ:PHVS - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.74) by $0.06.April 9, 2025 | marketbeat.comPharvaris reports Q4 EPS (EUR 0.64) vs. (EUR 0.95) last yearApril 8, 2025 | markets.businessinsider.comPharvaris Reports 2024 Financial Results and Business ProgressApril 8, 2025 | tipranks.comPharvaris Reports 2024 Financial Results and Advances HAE Treatment StudiesApril 7, 2025 | tipranks.comPharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateApril 7, 2025 | gurufocus.comPharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateApril 7, 2025 | globenewswire.comPharvaris (NASDAQ:PHVS) Sets New 12-Month Low - Time to Sell?Pharvaris (NASDAQ:PHVS) Reaches New 12-Month Low - What's Next?April 5, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - What's Next?Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Here's What HappenedApril 4, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Stock Price Down 4.3% - What's Next?Pharvaris (NASDAQ:PHVS) Trading Down 4.3% - What's Next?April 3, 2025 | marketbeat.comPharvaris says EC grants orphan designation to deucrictibantApril 2, 2025 | markets.businessinsider.comPharvaris Announces Orphan Designation Granted to Deucrictibant by the European CommissionApril 1, 2025 | globenewswire.comPharvaris (NASDAQ:PHVS) Trading Up 6% - Still a Buy?Pharvaris (NASDAQ:PHVS) Trading 6% Higher - Here's What HappenedMarch 28, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Trading Up 5.5% - Should You Buy?Pharvaris (NASDAQ:PHVS) Shares Up 5.5% - Still a Buy?March 22, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Stock Price Down 3.2% - Time to Sell?Pharvaris (NASDAQ:PHVS) Trading Down 3.2% - Should You Sell?March 20, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Short Interest Up 24.7% in FebruaryPharvaris (NASDAQ:PHVS - Get Free Report) was the recipient of a significant growth in short interest in February. As of February 28th, there was short interest totalling 487,300 shares, a growth of 24.7% from the February 13th total of 390,900 shares. Based on an average trading volume of 55,500 shares, the days-to-cover ratio is currently 8.8 days. Approximately 2.8% of the company's stock are short sold.March 18, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Gap Down - Should You Sell?Pharvaris (NASDAQ:PHVS) Shares Gap Down - Here's What HappenedMarch 18, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Trading 4.3% Higher - Still a Buy?Pharvaris (NASDAQ:PHVS) Trading 4.3% Higher - Here's What HappenedMarch 14, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Gap Down - What's Next?Pharvaris (NASDAQ:PHVS) Shares Gap Down - Here's What HappenedMarch 12, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Gap Up - Time to Buy?Pharvaris (NASDAQ:PHVS) Shares Gap Up - Should You Buy?March 11, 2025 | marketbeat.com Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address PHVS Media Mentions By Week PHVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHVS News Sentiment▼0.330.65▲Average Medical News Sentiment PHVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHVS Articles This Week▼242▲PHVS Articles Average Week Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ultragenyx Pharmaceutical News Arcellx News Metsera News Viking Therapeutics News Akero Therapeutics News Alvotech News Catalyst Pharmaceuticals News Crinetics Pharmaceuticals News Scholar Rock News Merus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHVS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
